Sun.Jan 07, 2024

article thumbnail

STAT+: Insitro, biotech AI’s quiet unicorn, unveils efforts in ALS, liver disease, and cancer at JPM

STAT

New artificial intelligence technologies made headlines last year for their ability to do everything from generating fake musical duets to understanding how proteins fold. But in biotech, one of the most well-funded AI players has been quiet. Insitro, a South San Francisco firm, was founded in 2018 by Daphne Koller, who had previously been a Stanford professor, a 2004 MacArthur “genius” grant recipient, and the co-founder and co-CEO of the online course company Coursera.

145
145
article thumbnail

After buying Novan's assets, Ligand crosses FDA finish line with molluscum gel Zelsuvmi

Fierce Pharma

Less than six months after Ligand Pharmaceuticals swooped in to buy Novan’s assets following the latter company’s bankruptcy, the purchase has paid off with an FDA approval. | Less than six months after Ligand Pharmaceuticals swooped in to buy Novan’s assets following the latter company’s bankruptcy, the purchase has paid off with an FDA approval.

FDA 106
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: What to expect from hospitals and health insurers at this year’s JPM Healthcare Conference

STAT

Nonprofit hospitals often get overshadowed at the J.P. Morgan Healthcare Conference, the health care industry’s swankiest investor meeting whose agenda is dominated by drugmakers and biotech companies. But hospitals are still the largest part of America’s health care economy, commanding nearly a third of the country’s $4.7 billion health care tab.

Insurance 111
article thumbnail

Lilly launches telehealth option for obesity and other drugs

pharmaphorum

Eli Lilly has launched a new website-based access programme for some drugs like its new obesity therapy Zepbound, opening up a new direct-to-consumer (DTC) channel that

103
103
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

No pain data yet from Vertex, and sky high deal expectations at JPM 2024

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up to get our biotech newsletter in your inbox. Greetings from JPM Week 2024! We’re coming to you live from San Francisco, where the industry’s biggest annual convocation is about to kick off — this time, without any substantive chatter about relocation to warmer, drier climes.

105
105
article thumbnail

JPM24: Option Care Health taps Palantir's AI for nurse scheduling, supply chain

Fierce Healthcare

Option Care Health, a provider of post-acute care and infusion services, inked a multi-year partnership with analytics company Palantir Technologies to use its artificial intelligence platform acro | Option Care Health, a provider of post-acute care and infusion services, inked a multi-year partnership with analytics company Palantir Technologies to use its artificial intelligence platform across its operations.

89

More Trending

article thumbnail

Why are Post-Approval Pregnancy Studies Post-Marking Requirements Rather Than Post-Marketing Commitments?

The FDA Law Blog

By McKenzie E. Cato — New Year’s is often associated with baby New Year and with resolutions, which in a convoluted way got us thinking about post-approval pregnancy studies. Lots of us start the new year with a resolution. Is it a commitment, or a requirement, and does the difference matter? For post-approval pregnancy studies, it most certainly does.

FDA 59
article thumbnail

Pressure Ulcer Infections – Antibiotic Selection

Med Ed 101

As much as I would like to say I’ve never seen a patient have a pressure ulcer infection, I have. Pressure ulcer infections can be an issue in my geriatric population. There are numerous clinical pearls to remember in managing these types of infections. First and foremost, topical antibiotics are NOT appropriate for the treatment […] The post Pressure Ulcer Infections – Antibiotic Selection appeared first on Med Ed 101.

52
article thumbnail

Temporary Cold Rooms in the Future Pharma Supply Chain

Pharmaceutical Commerce

The immediate availability, flexibility, and cutting-edge technology of rental cold storage units make them a popular solution for pharmaceutical cold chain challenges.

40